Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boric Acid vs Terconazole for Recurrent Vulvovaginal Candidiasis
NCT04208555Unknown
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Modality
- DNA Intercalators/Alkylators
01
Overview
Randomised trial of boric acid in vulvovaginal candidiasis (VVC) (2 arms). Primary endpoint: Mycological cure rate at Day 15. Status: unknown.
02
Drugs
boric acid
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT04208555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208555.